No scientific evidence to establish link between ibuprofen and worsening of Covid-19: Sanofi

Image
Press Trust of India New Delhi
Last Updated : Mar 20 2020 | 3:54 PM IST

French pharma major Sanofi on Friday said there is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID-19.

The company's statement comes in the wake of the World Health Organisation (WHO) stating earlier this week that people suffering from COVID-19-like symptoms should avoid self-medicating with ibuprofen after French authorities warned anti-inflammatory drugs could worsen the effects of the virus.

Countering it, Sanofi said the WHO has stated they are not aware of published clinical or population-based data on ibuprofen and the worsening of COVID-19 and based on currently available information, do not recommend against the use of ibuprofen.

"At Sanofi, our priority is the safety of our consumers, patients, employees, their families and the communities we are engaged with and ensuring the continuous supply of safe and efficacious products," Sanofi said in a statement.

As very recently stated by several health authorities, including European Medicines Agency (EMA), there is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID-19, it added.

In line with EU national treatment guidelines, healthcare professionals can continue prescribing (non-steroidal anti-inflammatory drugs) NSAIDs (like ibuprofen) for patient use, as per locally approved product information, it said.

The company is monitoring the situation closely and will review any new information that becomes available on this issue in the context of the pandemic, it added.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 20 2020 | 3:54 PM IST

Next Story